Online inquiry

IVTScrip™ mRNA-Anti-SLAMF7, ABBV-838(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1090MR)

This product GTTS-WQ1090MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets SLAMF7 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_001282588.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 57823
UniProt ID Q9NQ25
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SLAMF7, ABBV-838(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ1090MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6924MR IVTScrip™ mRNA-Anti-TNF, ENIA11(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ENIA11
GTTS-WQ7771MR IVTScrip™ mRNA-Anti-MMP9, GS-5745(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GS-5745
GTTS-WQ642MR IVTScrip™ mRNA-Anti-AOC3, 8c10(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 8c10
GTTS-WQ10378MR IVTScrip™ mRNA-Anti-APP, LY2062430(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LY2062430
GTTS-WQ11598MR IVTScrip™ mRNA-Anti-ERBB2, MGAH-22(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MGAH-22
GTTS-WQ13124MR IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PF-04360365
GTTS-WQ9361MR IVTScrip™ mRNA-Anti-PDCD1, INCMGA-00012(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA INCMGA-00012
GTTS-WQ12759MR IVTScrip™ mRNA-Anti-NOTCH1, OMP-52M51(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA OMP-52M51
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW